MCID: LCL006
MIFTS: 61

Localized Scleroderma malady

Categories: Genetic diseases, Rare diseases, Skin diseases, Immune diseases, Neuronal diseases, Nephrological diseases, Respiratory diseases, Bone diseases

Aliases & Classifications for Localized Scleroderma

About this section
Sources:
11Disease Ontology, 13DISEASES, 30ICD10, 31ICD10 via Orphanet, 32ICD9CM, 39MeSH, 40MESH via Orphanet, 45NCIt, 48NIH Rare Diseases, 50Novoseek, 54Orphanet, 62SNOMED-CT, 68UMLS, 69UMLS via Orphanet
See all MalaCards sources

Aliases & Descriptions for Localized Scleroderma:

Name: Localized Scleroderma 11 48 54 13 68
Morphea 11 48 50 68
Localized Fibrosing Scleroderma 48 54
Scleroderma, Circumscribed or Localized 11
Unspecified Circumscribed Scleroderma 11
 
Circumscribed Scleroderma Nos 11
Circumscribed Scleroderma 11
Scleroderma, Localized 48
Localised Morphoea 11
Localized Morphea 11

Characteristics:

Orphanet epidemiological data:

54
localized scleroderma:
Inheritance: Not applicable; Prevalence: 1-9/100000 (Europe); Age of onset: All ages; Age of death: normal life expectancy

Classifications:

Orphanet: 54 
Rare skin diseases


External Ids:

Disease Ontology11 DOID:8472
ICD1030 L94.0
ICD9CM32 701.0
MeSH39 D012594
NCIt45 C72069
Orphanet54 ORPHA90289
UMLS via Orphanet69 C0036420
ICD10 via Orphanet31 L94.0
MESH via Orphanet40 D012594

Summaries for Localized Scleroderma

About this section
NIH Rare Diseases:48 Localized scleroderma is characterized by thickening of the skin from excessive collagen deposits. collagen is a protein normally present in our skin that provides structural support. however, when too much collagen is made, the skin becomes stiff and hard. localized types of scleroderma are those limited to the skin and related tissues and, in some cases, the muscle below. internal organs are not affected by localized scleroderma, and localized scleroderma can never progress to the systemic form of the disease. often, localized conditions improve or go away on their own over time, but the skin changes and damage that occur when the disease is active can be permanent. for some people, localized scleroderma is serious and disabling. there are two generally recognized types of localized scleroderma: morphea and linear.   last updated: 4/3/2012

MalaCards based summary: Localized Scleroderma, also known as morphea, is related to calcinosis and rheumatoid arthritis, and has symptoms including exanthema, pruritus and Array. An important gene associated with Localized Scleroderma is MMP1 (Matrix Metallopeptidase 1), and among its related pathways are Syndecan-1-mediated signaling events and IL-9 Signaling Pathways and their Primary Biological Effects in Different Immune Cell Types. Affiliated tissues include skin, breast and skeletal muscle, and related mouse phenotypes are neoplasm and digestive/alimentary.

Wikipedia:71 Morphea, also called localized scleroderma or circumscribed scleroderma, is a form of scleroderma that... more...

Related Diseases for Localized Scleroderma

About this section

Diseases in the Systemic Scleroderma family:

Scleroderma, Familial Progressive localized scleroderma

Diseases related to Localized Scleroderma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 156)
idRelated DiseaseScoreTop Affiliating Genes
1calcinosis29.3CTGF, IL6, TGFB1, TNF
2rheumatoid arthritis29.0IL6, MMP1, MMP13, TGFB1, TNF
3systemic scleroderma11.6
4linear scleroderma11.3
5atrophoderma of pierini and pasini11.0
6diffuse large b-cell lymphoma10.3MMP1, TGFB1
7noonan syndrome 410.3MMP1, TGFB1
8chronic diarrhea due to guanylate cyclase 2c overactivity10.2DCN, MMP1
9miliaria10.2CTGF, TGFB1
10vps11-related autosomal recessive hypomyelinating leukodystrophy10.2IL6, TNF
11bilateral parasagittal parieto-occipital polymicrogyria10.2TGFB1, TNF
12stevens-johnson syndrome/toxic epidermal necrolysis10.2BMP6, DCN, TGFB1
13apert syndrome10.2BMP6, DCN, TGFB1
14leber congenital amaurosis10.2MMP1, SMAD3, TGFB1
15dyslexia 510.2IL6, TNF
16mass syndrome10.2BMP6, DCN, TGFB1
17geleophysic dysplasia 210.2CTGF, TGFB1
18distal trisomy 14q10.2TGFB1, TNF
19aortic atherosclerosis10.2IL6, TNF
20degenerative disc disease10.2IL6, TNF
21speech and communication disorders10.2BMP6, SMAD3, TGFB1
22zika fever10.1CTGF, MMP1, TGFB1
23lubani-al saleh-teebi syndrome10.1DCN, SMAD3, TGFB1
24anhidrosis10.1BMP6, CTGF, TGFB1
25unilateral multicystic dysplastic kidney10.1IL6, TNF
26thymic neuroendocrine carcinoma10.1IL6, TNF
27atherosclerosis10.1IL6, SELE
28swine influenza10.1IL6, TNF
29acquired thrombocytopenia10.1IL6, MMP1, TNF
30pulmonary valve insufficiency10.1CTGF, SMAD3, TGFB1
31drug dependence10.1IL6, TNF
32autosomal recessive type iv ehlers-danlos syndrome10.1IL6, MMP1, TNF
33anal paget's disease10.1IL6, TGFB1, TNF
34preaxial polydactyly of fingers10.1IL6, TGFB1, TNF
35hypoparathyroidism-retardation-dysmorphism syndrome10.1IL6, TGFB1, TNF
36rheumatoid factor-negative juvenile idiopathic arthritis without anti-nuclear antibodies10.1IL6, TGFB1, TNF
37carotenemia10.1IL6, MMP1, TNF
38reynolds syndrome10.1
39acute necrotizing encephalitis10.1CTGF, SMAD3, TGFB1
40transient tic disorder10.1BMP6, IL6, TNF
41hypotrichosis-lymphedema-telangiectasia-renal defect syndrome10.1SELE, TNF
42retinitis pigmentosa 5110.1IL6, MMP1, TNF
43labyrinthitis10.1IL6, TGFB1, TNF
44immunoglobulin g deficiency10.1IL6, TGFB1, TNF
45slate pneumoconiosis10.1BMP6, TNF
46myiasis10.1IL6, TGFB1, TNF
47orthostatic proteinuria10.1BMP6, IL6, TNF
48burns10.1IL6, TGFB1, TNF
49red cell phospholipid defect with hemolysis10.1BMP6, IL6, TNF
50baritosis10.1IL6, TGFB1, TNF

Comorbidity relations with Localized Scleroderma via Phenotypic Disease Network (PDN):


Systemic SclerodermaVulva Cancer

Graphical network of the top 20 diseases related to Localized Scleroderma:



Diseases related to localized scleroderma

Symptoms & Phenotypes for Localized Scleroderma

About this section

Human phenotypes related to Localized Scleroderma:

 54 64 (show all 16)
id Description HPO Frequency Orphanet Frequency HPO Source Accession
1 hyperpigmentation of the skin64 54 Very frequent (99-80%) HP:0000953
2 hypopigmentation of the skin64 54 Very frequent (99-80%) HP:0001010
3 cigarette-paper scars64 54 Very frequent (99-80%) HP:0001073
4 split hand64 54 Occasional (29-5%) HP:0001171
5 arthralgia64 54 Occasional (29-5%) HP:0002829
6 skeletal muscle atrophy64 54 Frequent (79-30%) HP:0003202
7 dermal atrophy54 Very frequent (99-80%)
8 scarring alopecia of scalp64 54 Occasional (29-5%) HP:0004552
9 flexion contracture of toe64 54 Occasional (29-5%) HP:0005830
10 stiff skin64 54 Very frequent (99-80%) HP:0030053
11 hemiatrophy54 Occasional (29-5%)
12 hemiatrophy of lower limb64 54 Occasional (29-5%) HP:0100557
13 hemiatrophy of upper limb64 54 Occasional (29-5%) HP:0100558
14 lipoatrophy64 54 Occasional (29-5%) HP:0100578
15 flexion contracture54 Occasional (29-5%)
16 myalgia64 54 Occasional (29-5%) HP:0003326

UMLS symptoms related to Localized Scleroderma:


exanthema, pruritus

MGI Mouse Phenotypes related to Localized Scleroderma according to GeneCards Suite gene sharing:

41
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00020069.2DCN, IL6, MMP1, SMAD3, TGFB1, TNF
2MP:00053819.1CTGF, DCN, IL6, SMAD3, TGFB1, TNF
3MP:00053888.6CTGF, DCN, IL6, SELE, TGFB1, TNF
4MP:00053858.1CTGF, IL6, MMP13, SELE, SMAD3, TGFB1
5MP:00053908.0BMP6, CTGF, DCN, IL6, MMP13, SMAD3
6MP:00053847.8CTGF, DCN, IL6, MMP13, SELE, SMAD3
7MP:00107717.7CTGF, DCN, IL6, MMP13, SELE, SMAD3
8MP:00053767.5CTGF, DCN, IL6, MMP1, MMP13, SELE
9MP:00053917.4CTGF, DCN, IL6, SELE, SMAD3, TGFB1
10MP:00053787.2BMP6, CTGF, DCN, IL6, MMP13, SELE

Drugs & Therapeutics for Localized Scleroderma

About this section

Drugs for Localized Scleroderma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 149)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1VaccinesPhase 46611
2
Bosentanapproved, investigationalPhase 2, Phase 3104147536-97-8104865
Synonyms:
-5-(o-methoxyphenoxy)-2-(2-pyrimidinyl)-4-pyrimidinyl]benzenesulfonamide
147536-97-8
174227-18-0
4-(1,1-Dimethylethyl)-N-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-(2,2'-bipyrimidin)-4-yl) benzenesulfornamide
4-(1,1-Dimethylethyl)-N-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-(2,2'-bipyrimidin)-4-yl)benzenesulfornamide
4-t-butyl-N-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2,2'-bipyrimidin-4-yl)benzenesulfonamide
4-tert-butyl-N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2,2'-bipyrimidin-4-yl]benzenesulfonamide
4-tert-butyl-N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-pyrimidin-2-ylpyrimidin-4-yl]benzenesulfonamide
AC-148
AC1L2XN2
Actelion
Bosentan
Bosentan (INN)
Bosentan [USAN:INN:BAN]
Bosentan hydrate
C27H29N5O6S
CHEBI:51450
CHEMBL957
CID104865
D07538
DB00559
 
EN002863
HMS2090N14
I06-1873
KS-5062
L001086
LS-31532
MolPort-003-845-300
NCGC00167440-01
PDSP1_001731
PDSP2_001714
Ro 47-0203
Ro 47-0203/039
Ro-47-0203
Ro-47-0203/029
Ro-47-0203/039
TL8001039
Tracleer
UNII-XUL93R30K2
bosentan
bosentanum
bosentán
p-tert-Butyl-N-(6-(2-hydroxyethoxy)-5-(o-methoxyphenoxy)-2-(2-pyrimidinyl)-4-pyrimidinyl)benzenesulfonamide
p-tert-Butyl-N-[6-(2-hydroxyethoxy)
3
Omeprazoleapproved, investigational, vet_approvedPhase 334873590-58-64594
Synonyms:
( -)-Omeprazole
(-)-Omeprazole
(S)-(-)-Omeprazole
(S)-Omeprazole
119141-89-8
131959-78-9
172964-80-6
2,3,5-Trimethylpyridine/Omeprazole
2-(((3,5-Dimethyl-4-methoxy-2-pyridyl)methyl)sulfinyl)-5-methoxy-1H-benzimidazole
2-({[3,5-dimethyl-4-(methyloxy)pyridin-2-yl]methyl}sulfinyl)-5-(methyloxy)-1H-benzimidazole
5-Methoxy-2-(((4-methoxy-3,5-dimethyl-2-pyridyl)methyl)sulfinyl)benzimidazole
5-Methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole
5-Methoxy-2[(4-methoxy-3,5-dimethyl-2-pyridyl)methylsulfinyl]-1H-benzimidazole
5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole
6-methoxy-2-[(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl]-1H-benzimidazole
73590-58-6
AC-401
AC1L1IIJ
AGI-010
AKOS005066653
AULCER
Antra
Antra MUPS
Audazol
Aulcer
Axagon
BIDD:GT0189
BPBio1_000425
BRD-A55962179-001-04-9
BSPBio_000385
Belmazol
Bio-0888
C07324
CAS-73590-58-6
CCRIS 7099
CHEBI:519601
CHEBI:7772
CHEMBL1503
CID4594
CPD000058847
Ceprandal
D00455
DB00338
DB00736
DM-3458
Danlox
Demeprazol
Desec
Dizprazol
Dudencer
Elgam
Emeproton
Emilok
Epirazole
Erbolin
Esomeprazole
Esomperazole
Esopral
Exter
Gasec
Gastrimut
Gastroloc
Gibancer
H 168-68
H 168/68
H-168/68
H168/68
HMS1528I05
HMS1569D07
HMS2052G17
HMS2090E16
HMS2090F11
HSDB 3575
I06-0705
IDI1_032523
Indurgan
Inhibitron
Inhipump
LS-7629
Lensor
Logastric
Lomac
Losec
Losec, Omesec, Prilosec, Zegerid, Omeprazole
Lucen
MLS000069373
MLS001076112
MLS001424148
Maybridge4_002645
Mepral
Miol
Miracid
MolPort-003-666-741
MolPort-003-807-515
MolPort-003-849-702
Mopral
Morecon
NCGC00016925-01
 
NCGC00016925-02
NCGC00021522-03
NCGC00021522-04
NCGC00021522-05
Nexiam
Nexium
Nexium IV
Nilsec
Nopramin
Nuclosina
O0359
O104_SIGMA
OMEP
OMP
OMZ
Ocid
Olexin
Olit
Omapren
Omebeta
Omebeta 20
Omed
Omegast
Omepradex
Omepral
Omeprazol
Omeprazol [INN-Spanish]
Omeprazole
Omeprazole (JAN/USP/INN)
Omeprazole Pellets
Omeprazole [USAN:INN:BAN:JAN]
Omeprazole delayed-release
Omeprazole magnesium
Omeprazolum
Omeprazolum [INN-Latin]
Omeprazon
Omeprazone
Omeprol
Omesek
Omez
Omezol
Omezolan
Omid
Omisec
Omizac
Ompanyt
Ortanol
Osiren
Ozoken
Paprazol
Parizac
Pepticum
Pepticus
Peptilcer
Prazentol
Prazidec
Prazolit
Prestwick0_000493
Prestwick1_000493
Prestwick2_000493
Prestwick3_000493
Prestwick_808
Prilosec
Prilosec (TN)
Prilosec OTC
Procelac
Proclor
Prysma
Ramezol
Regulacid
Result
S1389_Selleck
SAM001246900
SAN-15
SMR000058847
SPBio_002306
STK623746
Sanamidol
Secrepina
TL8005099
Tedec Ulceral
UNII-KG60484QX9
UPCMLD-DP075
UPCMLD-DP075:001
Ulceral
Ulcesep
Ulcometion
Ulcozol
Ulcsep
Ulsen
Ultop
Ulzol
Victrix
Zefxon
Zegerid
Zepral
Zimor
Zoltum
esomeprazol
omeprazole
4
AcetylcholineapprovedPhase 380551-84-3187
Synonyms:
ACh
Acetyl choline ion
Acetylcholine Chloride
Acetylcholine cation
 
Acetylcholinium: acetyl-Choline
Choline acetate
Choline acetate (ester)
O-Acetylcholine
acetylcholine chloride
5
LenograstimapprovedPhase 31220135968-09-1
Synonyms:
G-CSF (CHO cell derived)
Glycosylated recombinant G-CSF
Glycosylated recombinant granulocyte colony stimulating factor
 
Granulocyte colony stimulating factor 3 (CHO cell derived)
Granulocyte colony-stimulating factor lenograstim
Lenograstim (genetical recombination)
Lenograstim rDNA
6
Cyclophosphamideapproved, investigationalPhase 3, Phase 2, Phase 1293550-18-0, 6055-19-22907
Synonyms:
(+-)-Cyclophosphamide
(-)-Cyclophosphamide
(RS)-Cyclophosphamide
1-(bis(2-chloroethyl)amino)-1-oxo-2-aza-5-oxaphosphoridine
1-Bis(2-chloroethyl)amino-1-oxo-2-aza-5-oxaphosphoridin
2-[Bis(2-chloroethylamino)]-tetrahydro-2H-1,3,2-oxazaphosphorine-2-oxide
4-Hydroxy-cyclophosphan-mamophosphatide
50-18-0
60007-95-6
6055-19-2 (monohydrate)
75526-90-8
AC1L1EQQ
AI3-26198
ASTA
ASTA B518
Anhydrous cyclophosphamide
Asta B 518
B 518
B-518
BRN 0011744
BSPBio_002099
Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester
C 0768
C07888
C7H15Cl2N2O2P
CB 4564
CB-4564
CCRIS 188
CHEBI:4027
CHEMBL32520
CHEMBL88
CID2907
CP
CPA
CTX
CY
Ciclofosfamida
Ciclofosfamida [INN-Spanish]
Ciclofosfamide
Ciclophosphamide
Ciclophosphamide [INN]
Clafen
Claphene
Cycloblastin
Cyclophosphamid
Cyclophosphamide
Cyclophosphamide (INN)
Cyclophosphamide (TN)
Cyclophosphamide (anhydrous form)
Cyclophosphamide (anhydrous)
Cyclophosphamide Monohydrate
Cyclophosphamide Sterile
Cyclophosphamide anhydrous
Cyclophosphamide, (+-)-Isomer
Cyclophosphamides
Cyclophosphamidum
Cyclophosphamidum [INN-Latin]
Cyclophosphan
Cyclophosphane
Cyclophosphanum
Cyclophosphoramide
Cyclostin
Cyklofosfamid
Cyklofosfamid [Czech]
Cytophosphan
Cytophosphane
Cytoxan
Cytoxan (TN)
Cytoxan Lyoph
D,L-Cyclophosphamide
D07760
 
DB00531
DivK1c_000246
EINECS 200-015-4
EU-0100238
Endoxan
Endoxan R
Endoxan-Asta
Endoxana
Endoxanal
Endoxane
Enduxan
Genoxal
HMS2090A12
HSDB 3047
Hexadrin
IDI1_000246
KBio1_000246
KBio2_001338
KBio2_003906
KBio2_006474
KBio3_001319
KBioGR_000888
KBioSS_001338
LS-1302
LS-99787
Ledoxina
Lopac-C-0768
Lopac0_000238
Lyophilized Cytoxan
Mitoxan
MolPort-001-783-420
N,N-Bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide
N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
NCGC00015209-01
NCGC00015209-03
NCGC00015209-06
NCGC00091741-02
NCGC00091741-03
NCI-C04900
NCI60_002097
NINDS_000246
NSC 26271
NSC-26271
NSC26271
NSC273033
NSC273034
Neosar
Occupation, cyclophosphamide exposure
Procytox
RCRA waste no. U058
Rcra Waste Number U058
Rcra waste number U058
Revimmune
S1217_Selleck
SK 20501
SPBio_001071
STK177249
STOCK2S-91217
Semdoxan
Sendoxan
Senduxan
Spectrum2_001146
Spectrum3_000370
Spectrum4_000304
Spectrum5_000795
Spectrum_000858
UNII-6UXW23996M
WLN: T6MPOTJ BO BN2G2G
Zyklophosphamid
Zyklophosphamid [German]
bis(2-Chloroethyl)phosphami de cyclic propanolamide
bis(2-Chloroethyl)phosphamide cyclic propanolamide ester
cyclophosphamide
7
Tadalafilapproved, investigationalPhase 3155171596-29-5110635
Synonyms:
(6R,12AR)-2,3,6,7,12,12a-hexahydro-2-methyl-6-(3,4-(methylenedioxy)phenyl) pyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione
(6R,12aR)-2,3,6,7,12,12a-Hexahydro-2-methyl-6-(3,4-(methylenedioxy)phenyl) pyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione
(6R,12aR)-2,3,6,7,12,12a-Hexahydro-2-methyl-6-(3,4-methylenedioxyphenyl)pyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione
(6R-trans)-6-(1,3-Benzodioxol-5-yl)-2,3,6,7,12,12a-hexahydro-2-methyl-pyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione
171596-29-5
1xoz
6-BENZO[1,3]dioxol-5-yl-2-methyl-2,3,6,7,12,12a-hexahydro-pyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione
AC1L380B
ADCIRCA
Acdirca
Adcirca
C429886
CHEBI:41488
CHEMBL779
CID110635
CPD000466321
Cialis
Cialis (TN)
Cialis, GF 196960, IC 351, ICOS 351, Tadalafil
D02008
DB00820
FT-0080116
GF 196960
GF-196960
 
HMS2051N17
HSDB 7303
IC 351
IC-351
ICOS 351
Ic351
KS-1117
LS-186558
LS-187015
LS-187770
Lilly brand of tadalafil
MLS000759426
MLS001165782
MLS001195644
MLS001424132
MolPort-002-885-864
S1512_Selleck
SAM001246586
SMR000466321
Tadalafil
Tadalafil (JAN/USAN/INN)
Tadalafil [USAN]
Tadanafil
UNII-742SXX0ICT
ZINC03993855
8
DopamineapprovedPhase 3383651-61-6, 62-31-7681
Synonyms:
(3H)-Dopamine
.Beta.-(3,4-Dihydroxyphenyl)ethylamine hydrochloride
.alpha.-(3,4-Dihydroxyphenyl)-.beta.-aminoethane
1,2-Benzenediol, 4-(2-aminoethyl)- (9CI)
1,2-Benzenediol, 4-(2-aminoethyl)-, hydrochloride
1,2-Benzenediol, 4-(2-aminoethyl)-, labeled with tritium
153C5321-5FEE-4B0B-8925-F388F0EEEBD1
2-(3,4-Dihydroxyphenyl)ethylamine
2-(3,4-dihydroxyphenyl)ethylamine
2-benzenediol
3,4-Dihydroxyphenethylamine
3,4-Dihydroxyphenethylamine hydrochloride
3,4-Dihydroxyphenylethylamine
3,4-dihydroxyphenethylamine
3-Hydroxtyramine
3-Hydroxytyramine
3-Hydroxytyramine Hydrobromide
3-Hydroxytyramine hydrochloride
4-(2-Aminoethyl)-1,
4-(2-Aminoethyl)-1,2-benzenediol
4-(2-Aminoethyl)-1,2-bezenediol
4-(2-Aminoethyl)-Pyrocatechol
4-(2-Aminoethyl)benzene-1,2-diol
4-(2-Aminoethyl)catechol
4-(2-Aminoethyl)pyrocatechol
4-(2-Aminoethyl)pyrocatechol hydrochloride
4-(2-aminoethyl)-pyrocatechol
50444-17-2
51-61-6
62-31-7 (HYDROCHLORIDE)
AC1L19S5
AC1Q54AX
AC1Q54AY
AKOS003790978
ASL 279
BIDD:ER0506
BPBio1_001123
BSPBio_001932
Biomol-NT_000001
C03758
CHEBI:18243
CHEMBL59
CID681
D07870
DB00988
Deoxyepinephrine
DivK1c_000780
Dopamin
Dopamina
Dopamina [INN-Spanish]
Dopamine
Dopamine (INN)
Dopamine (USAN)(*hydrochloride*)
Dopamine [INN:BAN]
Dopaminum
Dopaminum [INN-Latin]
Dopastat
Dophamine
Dynatra
EINECS 200-110-0
HSDB 3068
Hydroxytyramin
Hydroxytyramine
IDI1_000780
IP 498
Intropin
Intropin [*hydrochloride*]
KBio1_000780
 
KBio2_001492
KBio2_002388
KBio2_002484
KBio2_004060
KBio2_004956
KBio2_005052
KBio2_006628
KBio2_007524
KBio2_007620
KBio3_001152
KBio3_002867
KBio3_002962
KBioGR_001129
KBioGR_002388
KBioGR_002484
KBioSS_001492
KBioSS_002393
KBioSS_002491
KW-3-060
L-DOPAMINE
L000232
LDP
LS-159
Lopac-H-8502
Lopac0_000586
Medopa (TN)
MolPort-001-641-000
NCGC00015519-01
NCGC00015519-08
NCGC00096050-01
NCGC00096050-02
NCGC00096050-03
NCGC00096050-04
NCGC00096050-05
NINDS_000780
NSC 173182
NSC169105
NSC173182
Oprea1_088821
Oxytyramine
Pyrocatechol, 4-(2-aminoethyl)- (8CI)
Pyrocatechol, 4-(2-aminoethyl)-, hydrochloride
Revimine
Revivan
SPBio_001205
SPECTRUM1505155
ST048774
STK301601
Spectrum2_001023
Spectrum3_000406
Spectrum4_000525
Spectrum5_000945
Spectrum_001012
UNII-VTD58H1Z2X
UPCMLD0ENAT5885989:001
a-(3,4-Dihydroxyphenyl)-b-aminoethane
alpha-(3,4-Dihydroxyphenyl)-beta-aminoethane
cMAP_000036
cMAP_000065
dopamine
hydroxytyramine
intropin
m-Hydroxytyramine hydrochloride
nchembio.105-comp9
nchembio.107-comp4
nchembio.284-comp1
nchembio.78-comp16
nchembio.89-comp3
nchembio705-8
nchembio801-comp8
9
Imiquimodapproved, investigationalPhase 314099011-02-657469
Synonyms:
1-(2-Methylpropyl)-1H-imidazole[4,5-c]quinoline-4-amine
1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine
1-(2-methylpropyl)imidazo[4,5-c]quinolin-4-amine
1-Isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
1-isobutyl-1H-imidazo(4,5-c)quinolin-4-amine
1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
3M Brand of Imiquimod
4-Amino-1-isobutyl-1H-imidazo(4,5-c)quinoline
4-Amino-1-isobutyl-1H-imidazo[4,5-c]quinoline
99011-02-6
AC-529
AC1L1N2I
AC1Q4YO9
Aldara
Aldara (TN)
Aldara, Imiquimod
BB_SC-2107
BIDD:GT0859
Beselna
C056493
CHEBI:36704
CHEMBL1282
CID57469
D02500
DB00724
DZ-2636
FT-0080222
HMS2090M14
 
I06-0624
I06-2289
I0747
I5159_SIGMA
IMIQUIMOD
Imiquimod
Imiquimod (JAN/USAN/INN)
Imiquimod [USAN:INN]
Imiquimod acetate
Imiquimodum
LS-178395
MLS000083577
MTD-39
MolPort-002-507-845
NCGC00070736-02
NSC369100
R 837
R-837
S 26308
S-26308
S1211_Selleck
SMR000048307
STK583860
TL8006059
TMX-101
UNII-P1QW714R7M
ZINC19632912
Zartra
Zyclara
imiquimod
10
Domperidoneapproved, investigational, vet_approvedPhase 34957808-66-93151
Synonyms:
1-(3-(4-(5-chloro-2-oxo-2,3-Dihydrobenzo[D]imidazol-1-yl)piperidin-1-yl)propyl)-1H-benzo[D]imidazol-2(3H)-one
4-(5-Chloro-2-oxo-1-benzimidazolinyl)-1-[3-(2-oxobenzimidazolinyl)propyl]piperidine
5-24-02-00402 (Beilstein Handbook Reference)
5-Chloro-1-(1-(3-(2-oxo-1-benzimidazolinyl)propyl)-4-piperidyl)-2-benzimidazolinone
5-Chloro-1-[1-[3-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)propyl]-4-piperidinyl]- 1,3-dihydro-2H-benzimidazol-2-one
5-Chloro-1-[1-[3-(2-oxo-1-benzimidazolinyl)propyl]-4-piperidyl]-2-benzimidazolinone
5-chloro-1-(1-(3-(2-oxo-1-Benzimidazolinyl)propyl)-4-piperidyl)-2-benzimidazolinone
5-chloro-1-(1-(3-(2-oxo-2,3-Dihydrobenzo[D]imidazol-1-yl)propyl)piperidin-4-yl)-1H-benzo[D]imidazol-2(3H)-one
5-chloro-1-(1-(3-(2-oxo-2,3-dihydro-1H-benzimidazol-1-yl)propyl)-4-piperidinyl)-1,3-dihydro-2H-benzimidazol-2-one
5-chloro-1-{1-[3-(2-oxo-2,3-dihydro-1H-benzimidazol-1-yl)propyl]piperidin-4-yl}-1,3-dihydro-2H-benzimidazol-2-one
5-chloro-1-{1-[3-(2-oxo-2,3-dihydro-benzoimidazol-1-yl)-propyl]-piperidin-4-yl}-1,3-dihydro-benzoimidazol-2-one
57808-66-9
6-chloro-3-[1-[3-(2-oxo-3H-benzimidazol-1-yl)propyl]piperidin-4-yl]-1H-benzimidazol-2-one
83898-65-1 (maleate (1:1))
99497-03-7 (maleate)
AB00052423
AC-2037
AC1L1FAB
BPBio1_000620
BPBio1_001185
BRD-K38305202-001-02-6
BRN 0903774
BSPBio_002350
Biomol-NT_000022
C22H24ClN5O2
CHEBI:31515
CHEBI:464745
CHEMBL219916
CID3151
D-122
D01745
D122_SIGMA
DB01184
DivK1c_006921
Domperidon
Domperidona
Domperidona [INN-Spanish]
Domperidone (JAN/USAN/INN)
Domperidone [USAN:BAN:INN:JAN]
Domperidonum
Domperidonum [INN-Latin]
EINECS 260-968-7
EU-0100427
HMS1922N04
HMS2089C14
HMS2093N22
HS-0067
I01-0054
I14-14161
KBio1_001865
KBio2_000871
 
KBio2_003439
KBio2_006007
KBioGR_000354
KBioSS_000871
KW 5338
KW-5338
L000230
LS-33301
Lopac-D-122
Lopac0_000427
MLS000859942
MLS001306482
MLS002222324
Motilium
Motilium (TN)
NCGC00014670
NCGC00014670-05
NCGC00014670-13
NCGC00015306-01
NCGC00021472-02
NCGC00021472-03
NCGC00021472-04
NCGC00021472-05
NCGC00021472-06
NCGC00021472-07
NCGC00021472-08
NCGC00097773-01
NCI299589
NCI60_002512
NCIStruc1_001686
NCIStruc2_001819
NSC-299589
NSC299589
Nauzelin
Prestwick0_000461
Prestwick1_000461
Prestwick2_000461
Prestwick3_000461
Prestwick_794
R 33,812
R-33,812
R-33812
S2461_Selleck
SMR000326802
SPBio_002501
SPECTRUM2300212
STK622843
SpecPlus_000825
Spectrum4_000087
Spectrum_000391
UNII-5587267Z69
domperidone
11
Lidocaineapproved, vet_approvedPhase 2, Phase 31317137-58-63676
Synonyms:
.alpha.-(Diethylamino)-2,6-acetoxylidide
.alpha.-Diethylamino-2,6-dimethylacetanilide
.alpha.-Diethylaminoaceto-2,6-xylidide
.omega.-Diethylamino-2,6-dimethylacetanilide
137-58-6
2-(Diethylamino)-2',6'-acetoxylidide
2-(Diethylamino)-N-(2,6-dimethylphenyl)acetamide
2-Diethylamino-N-(2,6-dimethyl-phenyl)-acetamide
2-Diethylamino-N-(2,6-dimethylphenyl)acetamide
4-12-00-02538 (Beilstein Handbook Reference)
6108-05-0 (MONOHYDROCHLORIDE MONOHYDRATE))
6108-05-0 (mono-hydrochloride, mono-hydrate)
73-78-9 (mono-hydrochloride)
AB00053581
AC-10282
AC1L1GGQ
AC1Q2Z7J
AKOS001026768
ARONIS23855
After Burn Double Strength Gel
After Burn Double Strength Spray
After Burn Gel
After Burn Spray
Alphacaine
Anestacon
Anestacon Jelly
BIDD:GT0342
BPBio1_000197
BRD-K52662033-001-02-6
BRD-K52662033-003-05-5
BRN 2215784
BSPBio_000179
BSPBio_001359
BSPBio_003004
Bio-0767
Bio1_000379
Bio1_000868
Bio1_001357
Bio2_000079
Bio2_000559
C07073
C14H22N2O
CAS-73-78-9
CDS1_000283
CHEBI:6456
CHEMBL79
CID3676
CPD000058189
Cappicaine
Cito optadren
Cuivasil
D00358
DB00281
Dalcaine
Dentipatch
Dentipatch (TN)
DermaFlex
Diethylaminoaceto-2,6-xylidide
Dilocaine
DivK1c_000174
DivK1c_001323
Duncaine
EINECS 205-302-8
ELA-Max
EMBOLEX
Emla
Emla Cream
Esracaine
FT-0082378
Gravocain
HMS1791D21
HMS1989D21
HMS2051C21
HMS2089E15
HMS548M19
HSDB 3350
I01-2704
IDI1_000174
IDI1_033829
Isicaina
Isicaine
Jetocaine
KBio1_000174
KBio2_000079
KBio2_001598
KBio2_002647
KBio2_004166
KBio2_005215
KBio2_006734
KBio3_000157
KBio3_000158
KBio3_002224
KBioGR_000079
KBioGR_000599
KBioSS_000079
KBioSS_001598
L-Caine
L0156
L1026_SIGMA
L7757_SIGMA
LIDOCAINE (73-58-6 (MONOHYDROCHLORIDE)
LIDOPEN
LQZ
 
LS-805
Lanabiotic
Leostesin
Lida-Mantle
Lidocaina
Lidocaina [INN-Spanish]
Lidocaine (JP15/USP/INN)
Lidocaine (VAN)
Lidocaine Carbonate
Lidocaine Hydrocarbonate
Lidocaine Monohydrochloride
Lidocaine [USAN:INN:JAN]
Lidocainum
Lidocainum [INN-Latin]
Lidocaton
Lidoderm
Lidoject-1
Lidoject-2
Lignocaine
Lignocainum
Lingocaine
Lopac-L-5647
Lopac0_000669
MLS000069724
MLS000758263
MLS001074177
Maricaine
Maybridge1_002571
MolPort-001-783-478
N-(2,6-dimethylphenyl)-N(2),N(2)-diethylglycinamide
N-(2,6-dimethylphenyl)-N~2~,N~2~-diethylglycinamide
NCGC00015611-01
NCGC00015611-02
NCGC00015611-03
NCGC00015611-04
NCGC00015611-14
NCGC00022176-05
NCGC00022176-06
NCGC00022176-07
NCGC00022176-08
NCGC00022176-09
NINDS_000174
NSC 40030
NSC40030
Norwood Sunburn Spray
Octocaine
Octocaine-100
Octocaine-50
Prestwick0_000050
Prestwick1_000050
Prestwick2_000050
Prestwick3_000050
Remicaine
Rocephin Kit
Rucaina
S1357_Selleck
SAM001247018
SMR000058189
SPBio_001525
SPBio_002100
STK552033
Solarcaine
Solarcaine aloe extra burn relief cream
Solcain
Spectrum2_001343
Spectrum3_001392
Spectrum4_000070
Spectrum5_001549
Spectrum_001118
UNII-98PI200987
WLN: 2N2 & 1VMR B1 F1
Xilina
Xilocaina
Xilocaina [Italian]
Xllina
Xycaine
Xylestesin
Xylesthesin
Xylocain
Xylocaine
Xylocaine (TN)
Xylocaine 5% Spinal
Xylocaine CO2
Xylocaine Dental Ointment
Xylocaine Endotracheal
Xylocaine Test Dose
Xylocaine Viscous
Xylocaine-MPF
Xylocaine-MPF with Glucose
Xylocaine-Mpf
Xylocaine-Mpf with Glucose
Xylocard
Xylocitin
Xyloneural (free base)
Xylotox
Zilactin-L
Zingo
alfa-Dietilamino-2,6-dimetilacetanilide
alfa-Dietilamino-2,6-dimetilacetanilide [Italian]
alpha-Diethylamino-2,6-dimethylacetanilide
alpha-diethylamino-2,6-dimethylacetanilide
lidocaine
nchembio.65-comp16
α-diethylamino-2,6-dimethylacetanilide
12
Glucosamineapproved, NutraceuticalPhase 2, Phase 31913416-24-8439213
Synonyms:
(+)-2-amino-2-deoxy-D-glucopyranose
(2R,3R,4R,5S,6R)-3-amino-6-(hydroxymethyl)oxane-2,4,5-triol
(2S,5R)-3-amino-6-(hydroxymethyl)oxane-2,4,5-triol
(3R,4R,5S,6R)-3-amino-6-(hydroxymethyl)oxane-2,4,5-triol
14257-69-3
2-Amino-2-deoxy-D-Glucose
2-Amino-2-deoxy-D-glucopyranose
2-Amino-2-deoxy-D-glucose
2-Amino-2-deoxy-beta-D-glucopyranose
2-Amino-2-deoxyglucose
2-Aminoglucose
2-Deoxy-2-amino-D-glucose
2-Deoxy-2-aminoglucose
2-amino-2-deoxy-D-glucopyranose
2-amino-2-deoxyglucose
2351-15-7
28905-10-4
2B4D44B2-D5AC-4DA4-9BE6-A4AE9574E4A6
3416-24-8
4-04-00-02017 (Beilstein Handbook Reference)
58-87-7
58267-75-7
6490-70-6
880765-44-6
90-77-7
911653-84-4
AC1L2D1C
AC1L96WB
AC1L9B8P
AC1Q4UBH
BRN 1724602
BSPBio_002086
C00329
C08349
CHEBI:28393
CHEBI:47977
CHEMBL234432
CID18897
CID439213
CID441477
CPD0-1193
Chitosamine
Cosamin
D-(+)-Glucosamine
 
D-Glucosamine
D-glucosamine
D04334
DB01296
DivK1c_000261
EINECS 222-311-2
GCS
Glucosamina
Glucosamina [INN-Spanish]
Glucosamine (USAN/INN)
Glucosamine [USAN:INN]
Glucosaminum
Glucosaminum [INN-Latin]
HMS500N03
HSDB 7469
IDI1_000261
InChI=1/C6H13NO5/c7-3-5(10)4(9)2(1-8)12-6(3)11/h2-6,8-11H,1,7H2/t2-,3-,4-,5-,6-/m1/s1
KBio1_000261
KBio2_001311
KBio2_003879
KBio2_006447
KBio3_001306
KBioGR_000970
KBioSS_001311
LS-71671
MolPort-002-507-091
MolPort-003-944-937
NCGC00164421-01
NCGC00178826-01
NINDS_000261
SPBio_000477
STK801823
Spectrum2_000519
Spectrum3_000443
Spectrum4_000565
Spectrum5_000756
Spectrum_000831
Viartril-S
beta-D-Glucosamine
bmse000247
chitosamine
glucosamine
nchembio.189-comp4
nchembio.2007.41-comp7
nchembio.412-comp5
partially N-deacetylated poly-beta-1,6-N-acetyl-D-glucosamine
13Antirheumatic AgentsPhase 3, Phase 2, Phase 110956
14Phosphodiesterase InhibitorsPhase 31289
15Endothelin Receptor AntagonistsPhase 2, Phase 3218
16Calcium, DietaryPhase 3, Phase 2, Phase 15713
17Sildenafil CitratePhase 3331171599-83-0
18Phosphodiesterase 5 InhibitorsPhase 3589
19Antihypertensive AgentsPhase 2, Phase 3, Phase 14207
20Vasodilator AgentsPhase 3, Phase 23543
21insulinPhase 34646
22AntacidsPhase 31842
23AntiemeticsPhase 34022
24
Alginic acidPhase 3789005-32-7
Synonyms:
Alginate
E400
Gum levan
 
Kelacid
Levan gum
Norgine
Sazio
25Neurotransmitter AgentsPhase 318340
26Insulin, Globin ZincPhase 34645
27onabotulinumtoxinAPhase 3652
28Neuromuscular AgentsPhase 31180
29HemostaticsPhase 3, Phase 11443
30Protective AgentsPhase 3, Phase 1, Phase 27443
31
Proton pump inhibitorsPhase 31123
Synonyms:
 
PPIs
32Radiation-Protective AgentsPhase 3480
33Chelating AgentsPhase 3, Phase 21423
34incobotulinumtoxinAPhase 3662
35Gastrointestinal AgentsPhase 38402
36Autonomic AgentsPhase 310150
37CoagulantsPhase 3, Phase 11500
38Dopamine AgentsPhase 33836
39Dopamine AntagonistsPhase 31093
40Anti-Ulcer AgentsPhase 31842
41Botulinum ToxinsPhase 3697
42Cholinergic AgentsPhase 33992
43AnestheticsPhase 2, Phase 39596
44Anti-Arrhythmia AgentsPhase 2, Phase 33093
45AnticoagulantsPhase 2, Phase 3, Phase 12623
46AntimetabolitesPhase 2, Phase 3, Phase 112054
47Immunosuppressive AgentsPhase 3, Phase 2, Phase 113086
48Antineoplastic Agents, AlkylatingPhase 3, Phase 2, Phase 14603
49Adjuvants, ImmunologicPhase 32554
50Interferon InducersPhase 3294

Interventional clinical trials:

(show top 50)    (show all 79)
idNameStatusNCT IDPhase
1Influenza Vaccination in Patients With SclerodermaUnknown statusNCT01002508Phase 4
2Imiquimod in Children With Plaque MorpheaCompletedNCT00147771Phase 3
3Sildenafil Effect on Digital Ulcer Healing in sClerodErma SEDUCE STUDYCompletedNCT01295736Phase 3
4High Dose Cyclophosphamide for Treatment of SclerodermaCompletedNCT00501995Phase 3
5Effectiveness and Safety of Lidocaine for SclerodermaCompletedNCT00740285Phase 2, Phase 3
6A Randomized Control Trial to Assess the Efficacy of Tadalafil in Raynaud's Phenomenon in SclerodermaCompletedNCT01117298Phase 3
7Efficacy of Botulinum Toxin In Scleroderma-Associated Raynaud's SyndromeCompletedNCT02165111Phase 3
8Gastroesophageal Reflux Treatment in SclerodermaCompletedNCT01878526Phase 3
9Efficacy and Safety of Oral Bosentan in Pulmonary Fibrosis Associated With SclerodermaCompletedNCT00070590Phase 2, Phase 3
10Effect of Sildenafil on the Microcirculatory Blood Flow and Endothelial Progenitor Cells in Systemic SclerosisCompletedNCT01347008Phase 3
11Scleroderma Lung DiseaseCompletedNCT00004563Phase 3
12Imiquimod 5% Cream in Plaque-type Morphea: A Pilot, Prospective Open-label StudyWithdrawnNCT00230373Phase 3
13A Protocol Based Treatment for Debilitating Fibrosing Skin Disorders With (Anti-CD 20), Rituximab, Evaluating Safety and EfficacyUnknown statusNCT00936546Phase 2
14Zibotentan Better Renal Scleroderma Outcome StudyUnknown statusNCT02047708Phase 2
15Efficacy and Safety of Imatinib in SclerodermaCompletedNCT00479934Phase 2
16Ultraviolet B (UVB) Light Therapy in the Treatment of Skin Conditions With Altered Dermal MatrixCompletedNCT00129428Phase 1, Phase 2
17Effect of Bosentan in Scleroderma Renal CrisisCompletedNCT01241383Phase 2
18Digital Ischemic Lesions in Scleroderma Treated With Oral Treprostinil DiethanolamineCompletedNCT00775463Phase 2
19Safety Evaluation of Dasatinib in Subjects With Scleroderma Pulmonary FibrosisCompletedNCT00764309Phase 1, Phase 2
20Cyclophosphamide and rATG With Hematopoietic Stem Cell Support in Systemic SclerodermaCompletedNCT00278525Phase 2
21Oral Type I Collagen for Relieving SclerodermaCompletedNCT00005675Phase 2
22A Study to Evaluate the Safety and Efficacy of Abatacept in Patients With Diffuse Systemic Sclerosis (Scleroderma)CompletedNCT00442611Phase 1, Phase 2
23Diltiazem Gel Versus Nitroglycerin Ointment in Healing Process of Scleroderma Digital UlcersCompletedNCT02801305Phase 2
24Comparison of Therapeutic Regimens for Scleroderma Interstitial Lung Disease (The Scleroderma Lung Study II)CompletedNCT00883129Phase 2
25Psychological Treatments for SclerodermaCompletedNCT00007267Phase 2
26Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Subjects With Systemic Sclerosis With Interstitial Lung DiseaseCompletedNCT01559129Phase 2
27Pirfenidone Plus M-DDO Gel in Moderate and Severe AcneRecruitingNCT03076320Phase 1, Phase 2
28Atorvastatin for Microvascular Endothelial Function and Raynaud in Early Diffuse SclerodermaRecruitingNCT02370784Phase 2
29Treatment of Refractory Sever Systemic Scleroderma by Injection of Allogeneic Mesenchymal Stem CellsRecruitingNCT02213705Phase 1, Phase 2
30Riociguat in Scleroderma Associated Digital UlcersRecruitingNCT02915835Phase 2
31Oral Ifetroban to Treat Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial HypertensionRecruitingNCT02682511Phase 2
32IL1-TRAP, Rilonacept, in Systemic SclerosisActive, not recruitingNCT01538719Phase 1, Phase 2
33Neoadjuvant Vismodegib in Patients With Large and/or Recurrent Resectable Basal Cell CarcinomaNot yet recruitingNCT03035188Phase 2
34Proof of Concept Trial of Gleevec (Imatinib) in Active Diffuse SclerodermaTerminatedNCT01545427Phase 2
35Placebo Controlled Trial of Bosentan in Scleroderma PatientsTerminatedNCT00377455Phase 2
36A Pilot Study to Evaluate Topical Sodium Thiosulfate Therapy for Calcinosis CutisWithdrawnNCT01918904Phase 2
37A Study of the Safety and Tolerability of MEDI-551 in SclerodermaCompletedNCT00946699Phase 1
38A Study to Evaluate Safety and Tolerability of Multiple Doses of MEDI-546 in Adult Subjects With SclerodermaCompletedNCT00930683Phase 1
39Novel Rehabilitation Strategies to Improve Arm Function in Patients With SclerodermaRecruitingNCT02837549Phase 1
40Safety & Suitability of Dabigatran to Inhibit Thrombin in SclerodermaRecruitingNCT02426229Phase 1
41Safety and Value of Self Bone Marrow Transplants Following Chemotherapy in Scleroderma PatientsTerminatedNCT00040651Phase 1
42Comparative Effectiveness Trial in the Treatment of Pediatric Plaque MorpheaWithdrawnNCT02680717Phase 1
43Fractional Carbon Dioxide Laser Versus UVA 1 in Treatment of Localized SclerodermaUnknown statusNCT02002897
44Treatment Study Comparing UVA-1 Phototherapy Versus Placebo Treatment for MorpheaUnknown statusNCT01799174
45Empirical Comparative Study of Variation Blood Level Antibody Vitamin D at Scleroderma (SSc) Patients Compared Healthy PeoplesUnknown statusNCT01553890
46Prevention and Treatment of Digital Ulcers in Systemic SclerosisUnknown statusNCT01836263
47Treatment Study Comparing Medium or High Dose Uva-1 Treatment 3x/Week Versus Fluocinonide 0.05% Cream in the Treatment of Morphea.CompletedNCT00812188
48The CARRA RegistryCompletedNCT01697254
49UVA1 Light for Treatment of Scleroderma and Similar ConditionsCompletedNCT00476801
50Morbidity and Mortality Follow Up for the Scleroderma Lung StudyCompletedNCT01762449

Search NIH Clinical Center for Localized Scleroderma

Genetic Tests for Localized Scleroderma

About this section

Anatomical Context for Localized Scleroderma

About this section

MalaCards organs/tissues related to Localized Scleroderma:

36
Skin, Breast, Skeletal muscle, Bone, Brain, Testes, Bone marrow

Publications for Localized Scleroderma

About this section

Articles related to Localized Scleroderma:

(show top 50)    (show all 369)
idTitleAuthorsYear
1
Musculoskeletal MRI findings of juvenile localized scleroderma. (28091699)
2017
2
Localized scleroderma: clinical and epidemiological features with emphasis on adulthood- versus childhood-onset disease differences. (28271552)
2017
3
Anti-dense Fine Speckled 70 Autoantibodies in Japanese Children with Dermatomyositis, Localized Scleroderma, and Idiopathic Arthritis with Iridocyclitis. (28461535)
2017
4
Quantitative Assessment of Skin Stiffness in Localized Scleroderma Using Ultrasound Shear-Wave Elastography. (28457631)
2017
5
The role of local temperature and other clinical characteristics of localized scleroderma as markers of disease activity. (27943304)
2017
6
Correlation of clinical tools to determine activity of localized scleroderma in paediatric patients. (26138783)
2016
7
Measurement of transepidermal water loss in localized scleroderma. (26970329)
2016
8
Drug Survival and Predictors of Drug Survival for Methotrexate Treatment in a Retrospective Cohort of Adult Patients with Localized Scleroderma. (26983450)
2016
9
Is Localized Scleroderma Caused by Borrelia burgdorferi? (27387068)
2016
10
Evaluation of serum concentrations of the selected cytokines in patients with localized scleroderma. (26985179)
2016
11
Localized scleroderma en coup de sabre in the Neurology Clinic. (27456882)
2016
12
Localized Scleroderma: A Clinical Review. (27604889)
2016
13
Fractional carbon dioxide laser versus low-dose UVA-1 phototherapy for treatment of localized scleroderma:A a clinical and immunohistochemical randomized controlled study. (27510285)
2016
14
Lichen sclerosus associated with localized scleroderma: dermoscopy contribution. (27579757)
2016
15
Esophageal abnormalities in juvenile localized scleroderma: is it associated with other extracutaneous manifestations? (27693175)
2016
16
Oxidative stress parameters in localized scleroderma patients. (27591994)
2016
17
Neurological abnormalities in localized scleroderma of the face and head: a case series study for evaluation of imaging findings and clinical course. (27700194)
2016
18
Mild Cognitive Impairment as a single sign of brain hemiatrophy in patient with Localized Scleroderma and Parry-Romberg Syndrome. (27154452)
2016
19
Systemic sclerosis and localized scleroderma--current concepts and novel targets for therapy. (26577237)
2016
20
BILATERAL CHOROIDAL EXCAVATION IN JUVENILE LOCALIZED SCLERODERMA. (27533641)
2016
21
A systematic review of tools for determining activity of localized scleroderma in paediatric and adult patients. (27401109)
2016
22
Use of Mycophenolate Mofetil in Patients with Severe Localized Scleroderma Resistant or Intolerant to Methotrexate. (26582717)
2016
23
German guidelines for the diagnosis and therapy of localized scleroderma. (26819124)
2016
24
Lupus erythematosus and localized scleroderma coexistent at the same sites: a rare presentation of overlap syndrome of connective-tissue diseases. (27274545)
2016
25
Predictors of Longitudinal Quality of Life in Pediatric Localized Scleroderma. (27696700)
2016
26
A Case Report of Successful Treatment of Recalcitrant Childhood Localized Scleroderma with Infliximab and Leflunomide. (26161155)
2015
27
Durometry as an Outcome Measure in Juvenile Localized Scleroderma. (26302039)
2015
28
Clinical and laboratory features of systemic sclerosis complicated with localized scleroderma. (25582037)
2015
29
Systemic involvement in localized scleroderma/morphea. (26321403)
2015
30
Localized Scleroderma of Lower Extremities:Clinical and Magnetic Resonance Imaging Features. (26564453)
2015
31
Localized scleroderma: clinical spectrum and therapeutic update. (25672301)
2015
32
Juvenile localized scleroderma with port wine stain: coincidental or possible common pathogenetic association. (25814757)
2015
33
Peripheral blood cytokine and chemokine profiles in juvenile localized scleroderma: T-helper cell-associated cytokine profiles. (26254121)
2015
34
Localized Scleroderma Presenting as Port-wine Stains: Report of Two Cases and a Literature Review. (25791763)
2015
35
The efficacy of dantrolene sodium for muscle cramps in patients with localized scleroderma. (26559172)
2015
36
Recurrence rates in localized scleroderma (morphoea). (25776242)
2015
37
Successful autologous hematopoietic stem cell transplantation for a patient with rapidly progressive localized scleroderma. (25923607)
2015
38
Assessment of esophageal involvement in systemic sclerosis and morphea (localized scleroderma) by clinical, endoscopic, manometric and pH metric features: a prospective comparative hospital based study. (25888470)
2015
39
Localized scleroderma and regional inflammatory myopathy. (24569141)
2014
40
United Kingdom survey of current management of juvenile localized scleroderma. (24850875)
2014
41
A rare case of acquired partial lipodystrophy (Barraquer-Simons syndrome) with localized scleroderma. (23675994)
2014
42
A Patient with Localized Scleroderma Successfully Treated with Etretinate. (25408646)
2014
43
Parry Romberg syndrome with localized scleroderma: A case report. (25136439)
2014
44
Disease recurrence in localized scleroderma: a retrospective analysis of 344 patients with pediatric or adult-onset disease. (25381928)
2014
45
Down-regulation of microRNA-196a in the sera and involved skin of localized scleroderma patients. (25152444)
2014
46
Pirfenidone gel in patients with localized scleroderma: a phase II study. (25533576)
2014
47
Localized scleroderma variants: pharmacologic implications. (22905721)
2014
48
Lipomatosis of the mons pubis secondary to localized scleroderma (Morphea): first report of surgical management. (25370577)
2014
49
Co-existence of Lichen Sclerosus and Localized Scleroderma in Female Monozygotic Twins. (24841519)
2014
50
Recurrent myelitis in localized scleroderma. (25459261)
2014

Variations for Localized Scleroderma

About this section

Expression for genes affiliated with Localized Scleroderma

About this section
Search GEO for disease gene expression data for Localized Scleroderma.

Pathways for genes affiliated with Localized Scleroderma

About this section

Pathways related to Localized Scleroderma according to GeneCards Suite gene sharing:

(show top 50)    (show all 57)
idSuper pathwaysScoreTop Affiliating Genes
19.9MMP1, TGFB1
29.8IL6, TGFB1
39.8SMAD3, TGFB1
4
Show member pathways
9.8SMAD3, TGFB1
59.7TGFB1, TNF
69.7CTGF, SMAD3
79.7IL6, TNF
89.7IL6, TNF
99.5DCN, IL6, MMP1
10
Show member pathways
9.5MMP1, SMAD3, TGFB1
119.4IL6, SMAD3, TGFB1
12
Show member pathways
9.4IL6, SMAD3, TGFB1
13
Show member pathways
9.4IL6, SMAD3, TGFB1
14
Show member pathways
9.4IL6, SMAD3, TGFB1
15
Show member pathways
9.4IL6, SMAD3, TGFB1
16
Show member pathways
9.4CTGF, SMAD3, TGFB1
17
Show member pathways
9.4IL6, TGFB1, TNF
189.4IL6, TGFB1, TNF
19
Show member pathways
9.4IL6, TGFB1, TNF
209.4IL6, TGFB1, TNF
219.4IL6, TGFB1, TNF
229.4IL6, TGFB1, TNF
239.4IL6, TGFB1, TNF
249.4IL6, TGFB1, TNF
25
Show member pathways
9.3SMAD3, TGFB1, TNF
269.3IL6, SMAD3, TNF
279.3CTGF, IL6, TNF
289.3BMP6, SMAD3, TGFB1
299.3BMP6, SMAD3, TGFB1
30
Show member pathways
9.2MMP1, MMP13, TNF
319.2IL6, MMP1, SMAD3, TGFB1
329.2IL6, MMP1, SMAD3, TGFB1
339.1BMP6, MMP13, TGFB1
349.1IL6, MMP1, TGFB1, TNF
359.1IL6, MMP1, TGFB1, TNF
36
Show member pathways
9.0DCN, MMP1, MMP13, TGFB1
37
Show member pathways
9.0MMP1, SELE, TGFB1
389.0IL6, MMP1, SELE
399.0BMP6, DCN, IL6, TGFB1
40
Show member pathways
9.0IL6, SMAD3, TGFB1, TNF
419.0IL6, SMAD3, TGFB1, TNF
429.0IL6, SMAD3, TGFB1, TNF
438.9CTGF, IL6, TGFB1, TNF
448.9BMP6, CTGF, IL6, TGFB1
45
Show member pathways
8.9IL6, MMP1, MMP13, TNF
468.9IL6, SELE, TNF
478.9IL6, SELE, TNF
488.8BMP6, CTGF, SMAD3, TGFB1
498.7IL6, MMP1, SMAD3, TGFB1, TNF
50
Show member pathways
8.6IL6, MMP1, SELE, TNF

GO Terms for genes affiliated with Localized Scleroderma

About this section

Cellular components related to Localized Scleroderma according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1Golgi lumenGO:00057969.9DCN, DEFB1, TGFB1
2extracellular matrixGO:00310129.8DCN, MMP1, MMP13, TGFB1
3proteinaceous extracellular matrixGO:00055788.6CTGF, DCN, MMP1, MMP13, TGFB1
4extracellular regionGO:00055767.4BMP6, CTGF, DCN, DEFB1, IL6, MMP1
5extracellular spaceGO:00056156.8BMP6, CTGF, DCN, DEFB1, IL6, MMP13

Biological processes related to Localized Scleroderma according to GeneCards Suite gene sharing:

(show all 48)
idNameGO IDScoreTop Affiliating Genes
1cell-cell junction organizationGO:004521610.6SMAD3, TGFB1
2evasion or tolerance of host defenses by virusGO:001904910.6SMAD3, TGFB1
3lens fiber cell differentiationGO:007030610.6SMAD3, TGFB1
4positive regulation of extracellular matrix assemblyGO:190120310.5SMAD3, TGFB1
5positive regulation of pri-miRNA transcription from RNA polymerase II promoterGO:190289510.5SMAD3, TGFB1
6positive regulation of collagen biosynthetic processGO:003296710.5CTGF, TGFB1
7negative regulation of myoblast differentiationGO:004566210.5TGFB1, TNF
8epithelial cell proliferation involved in salivary gland morphogenesisGO:006066410.5IL6, TNF
9positive regulation of mononuclear cell migrationGO:007167710.4TGFB1, TNF
10regulation of bindingGO:005109810.4SMAD3, TGFB1
11regulation of striated muscle tissue developmentGO:001620210.4SMAD3, TGFB1
12negative regulation of lipid storageGO:001088810.4IL6, TNF
13regulation of transforming growth factor beta receptor signaling pathwayGO:001701510.4SMAD3, TGFB1
14positive regulation of protein complex assemblyGO:003133410.4TGFB1, TNF
15positive regulation of chemokine productionGO:003272210.4IL6, TNF
16SMAD protein complex assemblyGO:000718310.4SMAD3, TGFB1
17positive regulation of SMAD protein import into nucleusGO:006039110.4BMP6, TGFB1
18protein import into nucleus, translocationGO:000006010.4TGFB1, TNF
19positive regulation of chondrocyte differentiationGO:003233210.3BMP6, SMAD3
20acute inflammatory responseGO:000252610.3DEFB1, IL6
21endochondral ossificationGO:000195810.2BMP6, MMP13
22extracellular matrix disassemblyGO:002261710.2DCN, MMP1, MMP13
23extrinsic apoptotic signaling pathwayGO:009719110.1SMAD3, TGFB1, TNF
24positive regulation of NF-kappaB transcription factor activityGO:005109210.1IL6, TGFB1, TNF
25positive regulation of peptidyl-serine phosphorylationGO:003313810.1IL6, TGFB1, TNF
26positive regulation of protein kinase B signalingGO:005189710.1IL6, TGFB1, TNF
27negative regulation of mitotic cell cycleGO:004593010.1SMAD3, TGFB1, TNF
28negative regulation of gene expressionGO:001062910.0CTGF, TGFB1, TNF
29positive regulation of epithelial cell proliferationGO:005067910.0BMP6, IL6, TGFB1
30positive regulation of nitric oxide biosynthetic processGO:004542910.0IL6, SMAD3, TNF
31positive regulation of bone mineralizationGO:003050110.0BMP6, SMAD3, TGFB1
32positive regulation of protein phosphorylationGO:000193410.0CTGF, TGFB1, TNF
33response to organic cyclic compoundGO:001407010.0CTGF, IL6, TGFB1
34response to woundingGO:000961110.0CTGF, IL6, TGFB1
35leukocyte tethering or rollingGO:005090110.0SELE, TNF
36T cell activationGO:004211010.0IL6, SMAD3, TGFB1
37agingGO:00075689.9CTGF, DCN, IL6, TGFB1
38defense response to Gram-positive bacteriumGO:00508309.8DEFB1, IL6, TNF
39SMAD protein signal transductionGO:00603959.8BMP6, SMAD3, TGFB1
40response to glucocorticoidGO:00513849.8BMP6, IL6, TNF
41negative regulation of fat cell differentiationGO:00455999.7IL6, SMAD3, TGFB1, TNF
42positive regulation of ERK1 and ERK2 cascadeGO:00703749.7CTGF, IL6, TGFB1, TNF
43leukocyte migrationGO:00509009.4MMP1, SELE, TGFB1, TNF
44positive regulation of gene expressionGO:00106289.3CTGF, IL6, SMAD3, TGFB1, TNF
45wound healingGO:00420609.1DCN, IL6, SMAD3, TGFB1
46immune responseGO:00069558.9BMP6, DEFB1, IL6, SMAD3, TNF
47positive regulation of transcription from RNA polymerase II promoterGO:00459448.8BMP6, DCN, IL6, SMAD3, TGFB1, TNF
48inflammatory responseGO:00069548.8BMP6, IL6, SELE, TGFB1, TNF

Molecular functions related to Localized Scleroderma according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1collagen bindingGO:00055189.9DCN, MMP13, SMAD3
2cytokine activityGO:00051259.4BMP6, IL6, TGFB1, TNF
3growth factor activityGO:00080839.3BMP6, CTGF, IL6, TGFB1
4transforming growth factor beta receptor bindingGO:00051609.3BMP6, SMAD3, TGFB1

Sources for Localized Scleroderma

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
27GTR
28HGMD
29HMDB
30ICD10
31ICD10 via Orphanet
32ICD9CM
33IUPHAR
34KEGG
37MedGen
39MeSH
40MESH via Orphanet
41MGI
44NCI
45NCIt
46NDF-RT
49NINDS
50Novoseek
52OMIM
53OMIM via Orphanet
57PubMed
58QIAGEN
63SNOMED-CT via Orphanet
67Tumor Gene Family of Databases
68UMLS
69UMLS via Orphanet